Diagnostics

Company to Participate in USA Corporate Executive Office Program
Epigenomics AG today announced the Veterans Administration - New York Harbor Healthcare System (VA-Manhattan) is commencing a study to assess the adherence impact of offering a blood-based colorectal cancer screening test and colonoscopy completion in patients who have refused colonoscopy and fecal immunochemical test (FIT).
Lucence Diagnostics today announced the launch of the world’s first molecular test to distinguish breast fibroadenoma, the commonest benign breast tumor, from phyllodes tumor, a less common tumor that may be malignant.
Hundreds of millions of dollars have been pledged by billionaires to advance scientific research.
The quantitative next-generation sequencing blood test for infectious diseases makes an international impact
The Baltimore Longitudinal Study of Aging was launched in 1958 by the National Institutes of Health. The idea was to follow and study the lives of healthy, active people over their lifetimes, rather than after they were dead.
October was a busy month as multiple biopharma companies made their debut as publicly traded entities and even more companies filed their intentions to go public with an initial public offering. BioSpace takes a look back at some of the key IPOs of the month.
Genetic testing has become an important medical standard for families with known histories of hereditary disease. Individuals who choose to go through the mental and emotional process of taking a genetic test and absorbing the potentially life-changing conclusions may be disturbed to find out that results of such tests are not always consistent.
PRESS RELEASES